HEALTH TECHNOLOGY

Tegria Acquires KenSci in Order to Assist Healthcare Organizations in Gaining New Insights from Data

Tegria | June 28, 2021

Tegria Acquires KenSci in Order to Assist Healthcare Organizations in Gaining New Insights from Data

Tegria announced today the purchase of KenSci, a leader in artificial intelligence systems and healthcare applications with origins in Microsoft's Azure4Research program and the University of Washington.

 

KenSci, which was founded in 2015, has received recognition for its AI platform and solutions that integrate the latest descriptive and predictive analytics technology, assisting healthcare organizations in modernizing their workflows and powering a digital, data-driven, value-based healthcare system. Customers of KenSci, which include providers, payers, and medical device manufacturers, are using advanced analytics and artificial intelligence in their operational, clinical, and care workflows, thus enhancing care experiences and health outcomes. KenSci applications are based on responsible and explainable AI models that aid in making healthcare more efficient, fair, and accountable.

 

Its services are cloud-based and built on Microsoft Azure. Customers of KenSci have also benefitted from the company's strong relationships with industry leaders. In 2020, Microsoft honored KenSci, its US Healthcare Partner of the Year.

 

"Unlocking data to provide insights is the key to making healthcare better for everyone," said Wasif Rasheed, Providence's chief revenue and growth officer. Tegria is set to debut in October 2020. "KenSci has been assisting clients in getting more out of their data for many years, and they understand the critical roles that innovation and collaboration play in accelerating change across all aspects of care. KenSci, when combined with Tegria's industry expertise and a wide variety of solutions, has the potential to have a significant effect on healthcare worldwide. KenSci has arrived in Tegria, and we couldn't be happier."

 

KenSci's AI-powered platform draws insights from data, resulting in improved patient experiences, more accurate diagnoses, and more efficient processes. KenSci automates data preparation across many sources, including real-time and unstructured data, and maps it into the industry-standard schema, preparing it for machine learning models. KenSci's platform is also designed to be versatile and customizable, allowing clients to build their applications.

 

"If you can predict, you have the potential to influence and enhance health outcomes," stated Sudarshan Chitre, CEO of KenSci. "AI and advanced analytics technologies are changing how healthcare companies use data to enhance human health and care outcomes. Tegria will allow us to expedite this transition on a larger scale while also providing instant value to our clients via AI-driven insights. We are thrilled to be joining Tegria so that we may write the next chapter together."

 

KenSci's technology is supported by substantial peer-reviewed research published by The Institute of Electrical and Electronics Engineers (IEEE), The Association for Computing Machinery (ACM), The American Medical Informatics Association (AMIA), and other organizations. KenSci received HIMSS Health Innovation Awards in 2018 and 2019 and KLAS top ratings in healthcare AI in 2019 and 2020. KenSci was a Gartner Cool Vendor and a CMS AI Challenge finalist in 2019. KenSci is headquartered in Seattle and has offices in Singapore and India.

 

With KenSci, Tegria can expand the breadth and depth in electronic health record optimization, managed services, revenue cycle management, and other areas. KenSci will continue to serve its existing client base while also working with its new colleagues on integrated solutions for the global healthcare industry.

 

Tegria's financial advisor was Cascadia Capital, and its legal counsel was McDermott Will & Emery on this deal. Brentwood Capital Advisors served as the exclusive financial adviser for KenSci, while Wilson Sonsini Goodrich & Rosati acted as legal counsel.

 

About Tegria

Tegria, founded by Providence, is dedicated to creating health for a better world. Tegria assists healthcare organizations of all sizes in accelerating technological, clinical, and operational advancements that enable people to live the healthiest lifestyles possible. Tegria is a Seattle-based company with employees throughout the United States and internationally. It employs over 3,000 strategists, technologists, service providers, and scientists committed to providing value to customers.

Spotlight

Healthix is using the Verato Universal MPI to automate its data stewardship and improve its patient matching. Using its game-changing “referential matching” approach, the Verato Universal MPI is automatically resolving millions of Healthix’s most difficult matches, a process that would otherwise require time-consuming manual review by data stewards.


Other News
DIGITAL HEALTHCARE

Nemaura Medical Launches Metabolic Health Program for Employers and Insurers

Nemaura Medical, Inc | January 14, 2022

Nemaura Medical, Inc.(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the launch for employers and insurers of Miboko, a new metabolic health program using a non-invasive glucose sensor along with an AI mobile application. The Company’s goal is to achieve broad adoption of Miboko as a form of preventative medicine for a wide user base through these commercial channels and is aligned with the general trend in consumer digital healthcare. “Introducing Miboko to the population at-large through employers and insurers will allow Nemaura to reach a much wider audience in much faster fashion than solely relying on a direct-to-consumer campaign, and in the Western world, these institutions are the most reliable gateway toward wider adoption of preventative health maintenance practices. Being aware of one’s metabolic health and how the body uniquely regulates sugar is key to one’s health. Patients, of course, want to be as informed as possible about their health, and employers and insurers are also aligned with patients in that regard, given the massive productivity losses and healthcare costs at stake on a larger scale across their employee and insured base, respectively. Miboko can help address this substantial market opportunity through our non-invasive, revolutionary approach to healthcare.” Nemaura CEO Dr. Faz Chowdhury Nemaura has also submitted a Premarket Approval (PMA) to the United States Food and Drug Administration (FDA) for approval of its glucose monitoring device as a Class 3 medical device. The Company’s PMA was the subject an on-site FDA bioresearch monitoring (BIMO) audit that generated a single Form 483 observation, for which the Company has committed to a full response this quarter. A follow-up BIMO audit of the clinical investigator site has also been scheduled for the current financial quarter. Miboko has been in development for nearly two years and addresses a significant mass market opportunity that the Company believes could benefit roughly a third to half of the population by using a non-invasive glucose sensor to measure and monitor a user’s metabolic health score, which is based on glucose tolerance or insulin resistance. Those with prediabetes or obesity concerns -- or even those looking to maintain better health through more careful glucose control -- may benefit from such a metabolic health program. How one’s body metabolizes sugar is the main influencer of one’s appetite, weight, sleep quality, and energy and mood levels and even plays a critical factor in chronic diseases (beyond just diabetes), such as heart disease and dementia. At the heart of the Miboko offering is Nemaura’s non-invasive glucose sensor that is designed to measure insulin resistance, reported as a metabolic health score, and priced to be highly affordable with the program running for an initial two-year period. The program also uses a mobile app to provide users with personalized information by tracking their metabolism. A user can find out how well their body responds to sugar through their metabolic health score — and how what they eat and what they do every day uniquely affects their metabolic health. Along with the capability to follow metabolic health progress on the app, Miboko users receive weekly and monthly reports that show and explain their body’s unique metabolic health score and a breakdown of how each of their habits are impacting their overall health and wellbeing. Suggestions for small, manageable changes to daily routines, such as eating more or less of a certain kind of food or exercising at a different time of day to coincide with peak energy levels, provide Miboko users with personalized, usable data. About Nemaura Medical, Inc. Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies. Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being. The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

Read More

HEALTH TECHNOLOGY

Frost & Sullivan Awards proteanTecs Best Electronics Health Monitoring Technology

proteanTecs | December 23, 2021

proteanTecs, a leading developer of deep data analytics solutions for electronics health and performance monitoring, announced today it has won the 2021 Frost & Sullivan Best Practices Award for Global Electronics Health Monitoring Technology Innovation Leadership.Electronics have become an existential enabler for key industries, from Datacenter to Automotive, where 24/7 continuity with zero in-mission failures is pivotal. Therefore, it is necessary to guarantee these systems' reliability, bringing a key question to the fore: How can service providers, such as data center hyperscalers and car OEMs, track the health of electronic fleets working under extreme conditions while ensuring business resilience until the devices complete their lifetime? The award reviews the evolving landscape of electronics and presents the clear and critical need for deep data analytics across multiple industries and mission critical devices. The award declares, "Electronics health monitoring is essential to ensure these systems' functional continuity and reliability. proteanTecs offers a unique value proposition in the form of on-chip agents capable of extracting parametric data in various lifecycle stages. The Universal Chip Telemetry (UCT) enabled Proteus deep data analytics platform provides actionable insights and alerts to users along the value chain based on common, correlated, and predictive data. This allows users to take immediate action to ensure uptime and improve power, performance, and reliability." "By weaving data science together with on-chip visibility, proteanTecs' solutions deliver an unprecedented clarity at each step of the system's lifecycle", observed Sushrutha Sadashiva, Industry Analyst. "Frost & Sullivan presents Best Practices Awards to companies that inspire growth in their industries. These leaders identify emerging trends before they become the market standard and create solutions that drive differentiation and sustainable growth. They are the game changers," said Jeff Frigstad, Global Sr. Vice President, Best Practices, Frost & Sullivan. Frost & Sullivan applies a rigorous process to evaluate multiple nominees for each award category, with a detailed evaluation of best practice criteria across several dimensions. "Frost & Sullivan is at the center of the ecosystem for best practice cultivation, with cutting-edge insights that are singularly focused on reshaping the world through managed growth. It is a great honor to be recognized by them as the technology innovation leader in the Global Electronics Health Monitoring industry." Shai Cohen, proteanTecs co-founder and CEO About Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 60 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. About proteanTecs proteanTecs is a leading provider of deep data monitoring solutions for advanced electronics in the Datacenter, Automotive, Communications and Mobile markets. Based on Universal Chip Telemetry™ (UCT), the company provides system health and performance monitoring, from production to the field. By applying machine learning to novel data created by on-chip UCT agents, the company's analytics platform delivers predictive insights and visibility, leading to new levels of quality, reliability and scale. Founded in 2017, the company is headquartered in Israel with offices in New Jersey, California, India and Taiwan.

Read More

HEALTH TECHNOLOGY

Stryker, One of the World’s Leading Medical Technology Companies, announces definitive agreement to acquire Vocera Communications

Stryker | January 07, 2022

Strykerannounced today a definitive merger agreement to acquire all of the issued and outstanding shares of common stock of Vocera Communications, Inc.for $79.25 per share, or a total equity value of approximately $2.97 billion and a total enterprise value of approximately $3.09 billion (including convertible notes). Vocera, which was founded in 2000, has emerged as a leading platform in the digital care coordination and communication category. The importance of this growing segment has continued to expand throughout the pandemic as it aims to reduce cognitive overload for caregivers and enables them to deliver the best patient care possible. Vocera brings a highly complementary and innovative portfolio to Stryker’s Medical division that will address the increasing need for hospitals to connect caregivers and disparate data-generating medical devices, which will help drive efficiencies and improve safety and outcomes. Vocera’s highly developed software competency, unique and innovative hardware solutions, and the ability to securely enable remote communication between patients and their families, complements Stryker's Advanced Digital Healthcare offerings. The combined business will further advance Stryker’s focus on preventing adverse events throughout the continuum of care. “This acquisition underscores our commitment and focus on our customer. Vocera will help Stryker significantly accelerate our digital aspirations to improve the lives of caregivers and patients.” Kevin Lobo, Chair and Chief Executive Officer, Stryker “Today’s milestone represents an exciting opportunity for Vocera given the clear alignment of mission, goals and culture between our two organizations and our ability to drive even greater economic and clinical value for our customers,” said Brent Lang, Chairman and Chief Executive Officer, Vocera. Under the terms of the merger agreement, Stryker will commence a tender offer for all outstanding shares of common stock of Vocera for $79.25 per share in cash. The boards of directors of both Stryker and Vocera have unanimously approved the transaction. The closing of the transaction is subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, completion of the tender offer and other customary closing conditions. The acquisition is expected to close in the first quarter of 2022 and is expected to have a neutral impact to net earnings per diluted share in 2022. About Stryker Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. About Vocera The mission of Vocera Communications, Inc. is to improve the lives of healthcare professionals, patients, and families. Founded in 2000, Vocera provides clinical communication and workflow solutions that help protect and connect team members, increase operational efficiency, enhance quality of care and safety, and humanize the healthcare experience. More than 2,300 facilities worldwide, including nearly 1,900 hospitals and healthcare facilities, have selected Vocera solutions to enable their workforce to communicate and collaborate with co-workers and engage with patients and families. Mobile workers can choose the right device for their role or task, including smartphones or one of the company’s wearable communication devices, and use voice commands to easily reach people by name, role, or group. The hands-free Vocera Smartbadge was named to TIME’s list of the 100 Best Inventions of 2020. Vocera solutions can integrate with more than 150 clinical and operational systems, including electronic health records, nurse call systems, ventilators, physiological monitors, and more. In addition to healthcare, Vocera solutions are found in aged care facilities, veterinary hospitals, schools, luxury hotels, retail stores, power facilities, and more.

Read More

HEALTH TECHNOLOGY

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics.Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs?Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely.Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779 Olga@GIANT.health

Read More

Spotlight

Healthix is using the Verato Universal MPI to automate its data stewardship and improve its patient matching. Using its game-changing “referential matching” approach, the Verato Universal MPI is automatically resolving millions of Healthix’s most difficult matches, a process that would otherwise require time-consuming manual review by data stewards.

Resources